Healthcare - Biotechnology - NASDAQ - US
$ 1.09
1.87 %
$ 26.1 M
Market Cap
-1.82
P/E
CASH FLOW STATEMENT
-10.3 M
OPERATING CASH FLOW
2.03 M
INVESTING CASH FLOW
5.01 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
RenovoRx, Inc.
| Net Income | -10.2 M |
| Depreciation & Amortization | 6 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 1.08 M |
| Change in Working Capital | 605 K |
| Others | -1.13 M |
| Free Cash Flow | -10.3 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (10.2) | (9.9) | (6.3) | (3.8) | (3.8) |
| Depreciation & Amortization | 0 | 6 K | 9 K | 0 | 0 |
| Deferred Income Tax | 0 | (0.6) | (0.2) | 0 | 0 |
| Stock Based Compensation | 1.1 | 0.6 | 0.1 | 50 K | 38 K |
| Other Operating Activities | (1.7) | 0.6 | 0.7 | 0.5 | 8 K |
| Change in Working Capital | 0.6 | 0.4 | (0.3) | (0.3) | 0.4 |
| Cash From Operations | (10.3) | (8.8) | (5.9) | (3.5) | (3.4) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | 0 | 0 | 15 K | 0 | 0 |
| Other Items | 2.0 | (2.0) | 0 | 0 | 1 K |
| Cash From Investing Activities | 2.0 | (2.0) | 15 K | 0 | 1 K |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 2.0 | 3.2 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8 K | 42 K | 17.4 | 21 K | 0 |
| Cash From Financing Activities | 5.0 | 42 K | 19.3 | 3.2 | 0 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (3.2) | (10.8) | 13.4 | (0.3) | (3.4) |
| FREE CASH FLOW | |||||
| Free Cash Flow | (10.3) | (8.8) | (5.9) | (3.5) | (3.4) |